Source:http://linkedlifedata.com/resource/pubmed/id/12201361
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2002-8-30
|
| pubmed:abstractText |
Flt3 ligand (FL) administration markedly increases bone marrow (BM) stem cells and immature dendritic cells. We investigated the influence of CD40-CD40Ligand (CD154) pathway blockade on antidonor immunity, cytokine production, microchimerism and heart graft survival in BALB/c (H2d) recipients of fully allogeneic C57BL/10 (H2b) FL-mobilized BM (FL-BM) or normal BM. Anti-CD40L mAb strongly suppressed anti-donor T-cell proliferative responses in recipients of either normal or FL-BM, but was less efficient in inhibiting antidonor cytolytic T-cell (CTL) activity, especially in recipients of FL-BM. Interestingly, CD40L blockade was more effective in recipients of multiple compared with single donor BM infusions. Anti-donor cytokine responses revealed complete impairment of IFN-gamma, IL-4 and IL-10 production in recipients of normal BM and CD40L mAb. By contrast, and in agreement with the CTL data, mice given FL-BM retained ability to produce IFN-gamma CD40-CD40L blockade did not promote microchimerism, as evidenced by immunohistology and real time polymerase chain reaction. Nevertheless, anti-CD40L mAb enhanced heart allograft survival in recipients of FL-BM, but the effect was inferior to that achieved with normal BM. These data provide insight into the influence of growth factor-expanded donor BM and costimulation blockade on antidonor immune reactivity and transplant outcome. The comparatively poor outcome obtained using FL-BM plus anti-CD40L mAb in this model may be ascribed to the failure of effectively interdicting antidonor CTL activity.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1600-6135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
609-17
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12201361-Animals,
pubmed-meshheading:12201361-Bone Marrow Transplantation,
pubmed-meshheading:12201361-CD40 Ligand,
pubmed-meshheading:12201361-Flow Cytometry,
pubmed-meshheading:12201361-Graft Survival,
pubmed-meshheading:12201361-Heart Transplantation,
pubmed-meshheading:12201361-Immunosuppression,
pubmed-meshheading:12201361-Ligands,
pubmed-meshheading:12201361-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:12201361-Membrane Proteins,
pubmed-meshheading:12201361-Mice,
pubmed-meshheading:12201361-Mice, Inbred BALB C,
pubmed-meshheading:12201361-Mice, Inbred C3H,
pubmed-meshheading:12201361-Mice, Inbred C57BL,
pubmed-meshheading:12201361-Polymerase Chain Reaction,
pubmed-meshheading:12201361-T-Lymphocytes,
pubmed-meshheading:12201361-Time Factors,
pubmed-meshheading:12201361-Transplantation, Homologous
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154).
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|